New evidence in obesity and cardiometabolic risk centered on oral semaglutide’s effects across multiple endpoints in overweight and obese populations. A systematic review and meta-analysis published in BMC Pharmacology and Toxicology assessed how oral semaglutide changes cardiometabolic risk factors, extending discussion beyond glucose control. Separately, the broader nutrition-medical interface continues to attract research focus, including observational evidence tying common food preservatives to elevated blood pressure and cardiovascular outcomes. While that latter work is not a therapy study, it adds to the evidence base shaping risk stratification in cardiometabolic care. For drug developers and clinicians, the combined items reinforce how metabolic therapy narratives are widening toward multimodal risk management—while nutrition science is increasingly informing risk frameworks.